CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Jun. 30, 2011
CURRENT ASSETS:
Cash and cash equivalents	$ 9,389	$ 42,829
Short term bank deposit	21,397
Marketable securities	7,023
Prepaid expenses	45	314
Accounts receivable from the Office of the Chief Scientist	203
Other accounts receivable	135	154
Total current assets	38,192	43,297
LONG-TERM ASSETS:
Long-term restricted deposits	1,287	179
Severance pay fund	522	452
Advance payment for new facility construction	2,400
Property and equipment, net	5,019	2,088
Total long-term assets	9,228	2,719
Total assets	47,420	46,016
CURRENT LIABILITIES
Trade payables	1,368	1,177
Accrued expenses	922	208
Deferred revenues	779
Advance payment from United Therapeutics	1,576
Other accounts payable	877	633
Total current liabilities	5,522	2,018
LONG-TERM LIABILITIES
Deferred revenues	3,505
Accrued severance pay	651	576
Total long-term liabilities	4,156	576
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common stock $0.00001 par value: Authorized: 100,000,000 shares Issued and outstanding: 46,448,051 shares as of June 30, 2012, 42,443,185 shares as of June 30, 2011
Additional paid-in capital	103,619	94,375
Accumulated deficit	(65,747)	(50,953)
Other comprehensive loss	(130)
Total stockholders' equity	37,742	43,422
Total liabilities and stockholders' equity	$ 47,420	$ 46,016